Management of Copper Deficiency and Cirrhosis-Induced Myelopathy
Diagnostic Approach
- Spinal MRI is mandatory to exclude other causes of myelopathy, specifically vitamin B12, thiamine, and copper deficiency, in patients with cirrhosis and myelopathy, as recommended by the European Association for the Study of the Liver (EASL) 1, 2, 3
- Measure serum copper, ceruloplasmin, vitamin B12, and thiamine levels in all patients presenting with myelopathy and cirrhosis, according to the EASL guidelines 1, 2, 3
Hepatic Myelopathy Characteristics
- Hepatic myelopathy is characterized by rapidly progressing spastic paraparesis without sensory deficit or sphincter dysfunction, present in >80% with extensive portosystemic shunts, and does not respond to standard hepatic encephalopathy therapies, as stated by the EASL 1, 2, 3
- Patients with hepatic myelopathy progress over months leading to wheelchair dependence, and liver transplantation should be considered as soon as possible, as recommended by the EASL with a 94% consensus 1, 2, 3
Treatment of Hepatic Myelopathy
- Liver transplantation is the recommended treatment for hepatic myelopathy, with patients who underwent liver transplantation having similar outcomes to those transplanted for other forms of hepatic encephalopathy, according to the EASL guidelines 1, 2, 3
- All portosystemic shunts must be closed during the transplantation procedure, as stated by the EASL 1, 2, 3
Monitoring and Prevention of Copper Toxicity
- In patients requiring copper supplementation, check serial levels every 6-12 months to ensure adequate but not excessive levels, as recommended by the EASL 4
- Regular monitoring of liver and renal function is essential during copper supplementation to prevent copper toxicity, which can cause severe multi-organ damage, according to the EASL guidelines 4